Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology

Maarten J. G. Leening1,2 · Karim D. Mahmoud1

Received: 11 October 2021 / Accepted: 2 November 2021 / Published online: 18 November 2021
© The Author(s) 2021

Keywords Non-inferiority · Randomized clinical trial · Statistics · Methods · Epidemiology · Cardiology

Randomized non-inferiority trials are designed to study whether an experimental treatment (or diagnostic test) is not unacceptably worse in terms of efficacy compared to the standard of care, whilst providing specific advantages over the standard of care justifying this comparison [1–3]. The magnitude by which the experimental treatment is acceptably less efficacious than the standard of care is commonly referred to as the non-inferiority margin. This pre-specified margin allows for constructing the null hypothesis stating that the experimental treatment is statistically significantly worse (i.e. inferior) than the standard of care. Rejecting this null hypothesis permits a conclusion of non-inferiority. The aforementioned specific non-efficacy advantages over the standard of care are referred to as non-efficacy benefits, and can for instance come in the form of lower probability of adverse events or complications, convenience of use, or lower costs.

The non-inferiority design lends itself particularly well to trials on de-intensifying or withholding treatment with known adverse effects. Elegant examples of such trials present both the implied non-efficacy benefit as a primary outcome (tested for superiority) and the potential loss in efficacy as a co-primary (or hierarchical secondary) outcome (tested for non-inferiority), hence aiming to demonstrate that de-intensified treatment comes with less adverse events balanced by acceptable losses in efficacy [4–7]. For example, consider a trial aimed to study whether withholding one of two antithrombotic medications prescribed after transcatheter aortic valve implantation, would result in less bleeding complications (primary endpoint tested for superiority; inferred non-efficacy benefit of de-intensifying antithrombotic treatment) without leading to an unacceptable higher number of thromboembolic events (secondary endpoint tested for non-inferiority) [5]. Although not so common, meta-analyses of trials have also employed non-inferiority designs to analyze aggregate data in order to answer non-inferiority questions with greater precision [8].

In this issue of the Eur J Epidemiol, Dr Acuna and colleagues make a case for ways to improve the reporting of non-inferiority trials by putting greater emphasis on non-efficacy benefits [9]. The work by Dr Acuna and colleagues provides a strong theoretical foundation with clear practical recommendations on how to implement non-efficacy benefits and non-inferiority margins into everyday reporting of non-inferiority trials. However, contemporary practices on this matter are less well documented. Hence, we aimed to evaluate the current scientific practice regarding the use and reporting of non-efficacy benefits and non-inferiority margins in clinical cardiology—a field of medicine with an ever increasing number of non-inferiority trials [3]. We focused on recent trials in high-impact journals as these generally serve as focal point for future studies to be modelled on.

Literature search and data collection

We aimed to identify recent high-impact non-inferiority trials in the field of clinical cardiology. Hereto, we restricted to studies published (in print or online) from January 1, 2019 onwards in the following leading general medical and cardiology journals: the New England Journal of Medicine, The
Lancet, the Journal of the American Medical Association, the British Medical Journal, the European Heart Journal, Circulation, and the Journal of the American College of Cardiology. Using PubMed (https://pubmed.ncbi.nlm.nih.gov/) we searched for “non-inferiority” or “noninferiority” in the aforementioned journals. References were screened for further evaluation based on title and abstract, aiming to identify randomized clinical trials employing a non-inferiority design in the field of clinical cardiology. Both authors extracted trial parameters from the full text manuscript (and online supplementary files if required so) by focusing on primary non-inferiority outcomes (or secondary outcomes only if primary outcomes were only tested for superiority).

The literature search was last updated on October 9, 2021.

If not reported in the original publication, we calculated the non-inferiority margin in terms of relative risk based on outcome (i.e. event rate or measurement) in the standard of care group:

Relative non-inferiority margin = [outcome + absolute non-inferiority margin] / outcome

We did this based on both the outcome in the standard of care group as anticipated during trial design, as well as based on the observed outcome in the standard of care group within the trial.

The proportional increase in relative non-inferiority margins due to overestimation of the anticipated outcome was calculated as follows:

Proportional increase in relative non-inferiority margin = [observed relative non-inferiority margin—1] / [anticipated relative non-inferiority margin—1]

Findings on non-efficacy benefits and non-inferiority margins

A total of 59 trials were included in our scoping review [4–8, 10–63].

Non-efficacy benefits

In 69% (n = 41) of the articles non-efficacy benefits could be retraced (or clearly inferred). Among those 41 articles, a minority provided a rationale for the magnitude of the non-inferiority margin in relation to the non-efficacy benefit at hand.

Non-efficacy benefits were most commonly (n = 23, 39%) related to anticoagulation strategies or comparing interventions that require different downstream anticoagulation strategies. Associated non-efficacy benefits included having to use less anticoagulants (with accompanying lower bleeding risk) or convenience to use anticoagulants without the need for therapeutic monitoring [5–8, 14, 17, 21, 22, 24, 28, 32, 33, 36, 40, 41, 44, 48, 58, 62, 63]. Another common non-efficacy benefit was the use of less invasive techniques to diagnose or treat a variety of cardiac conditions (n = 9, 15%) [19, 21, 23, 25–27, 42, 45, 54]. Among remaining non-efficacy benefits, interventions aiming to reduce hospital stay were frequent (n = 7, 12%) [12, 15, 19, 21, 26, 53, 60].

Non-inferiority margins

Most non-inferiority margins were expressed as event rates of clinical endpoints, such as death, cardiovascular events, or bleeding complications. Besides counting clinical endpoints, outcomes included restricted mean survival time to clinical events [41], chest tube drainage volume after coronary bypass surgery [60], number of blood transfusions after cardiac surgery [11], platelet activity parameters [39], coronary artery diameter stenosis [10], and specificity to diagnose significant coronary artery disease [4]. Non-inferiority margins were mostly defined as absolute increases of anticipated outcomes in the standard of care group (n = 39 endpoints, 63%), whereas within the remaining trials they were pre-specified as relative non-inferiority margins (n = 23 endpoints, 37%).

When anticipated outcomes in the standard of care group were reported (n = 55 endpoints), the magnitude thereof was overestimated compared to the actual observed outcomes in the standard of care group in 56% (n = 31 endpoints). Stratiﬁying these results by type of non-inferiority margin (absolute versus relative) showed that outcome in the standard of care group was overestimated in 62% (n = 24 endpoints) amongst trials with absolute non-inferiority margins, and in 44% (n = 7 endpoints) amongst trials with relative non-inferiority margins (χ² P = 0.23).

Overestimating the anticipated outcome in the standard of care arm whilst testing an absolute non-inferiority margin will result in a bias towards rejecting the null hypothesis (i.e. increasing the likelihood of claiming non-inferiority), since the corresponding relative non-inferiority margin will increase [2, 3]. For instance, one study comparing different aortic valve prostheses assumed that 30.8% of patients would have a complication within 30 days of implantation (i.e. anticipated outcome usual care) and an increase of up to 8.5% in complications would be acceptable (i.e. absolute non-inferiority margin; corresponding to a relative non-inferiority margin of 1.28 ([30.8 + 8.5] / 30.8)) [47]. However, in the trial only 9.6% of patients had a complication (i.e. observed outcome usual care) which resulted in an actually tested relative non-inferiority margin of 1.89 ([9.6 + 8.5] / 9.6), thereby rejecting the non-inferiority null hypothesis whilst allowing for a threefold higher frequency of complications (relative 89% increase instead of the anticipated 28% increase). If a relative non-inferiority margin of 1.28 would
have been tested, the likelihood of rejecting the null hypothesis of non-inferiority would have been markedly reduced by the lower than expected rate of complications observed (similar to a superiority trial with lower than expected event rates). The average increase in relative non-inferiority margin due to overestimation of the anticipated outcome (amongst trials with an absolute non-inferiority margin) was a factor 1.65, with outliers at 3.19 [13] and 3.21 [47]. Such overestimation induces substantial bias towards claiming non-inferiority in these trials. This was explicitly acknowledged as a major limitation by several trials in our literature review (e.g. [13, 17, 25, 47, 62]).

**Specific considerations related to non-efficacy benefits and non-inferiority margins**

**Uncertain or lack of non-efficacy benefit**

We encountered a substantial number of non-inferiority trials without clear non-efficacy benefits or perceived non-efficacy benefits based purely on theoretical grounds. This was clearly seen among trials comparing coronary stents or implantable valves from different manufacturers [10, 20, 31, 37, 43, 47, 50, 56, 57, 59], which can be considered studies to evaluate good substitutes [3] and often allowed for remarkable high anticipated relative non-inferiority margins > 1.5. A major concern here is the risk of biocreep when subsequent generations of stents or valves are only tested for non-inferiority against previous generations and at each comparison a loss of efficacy is permitted [3].

Non-efficacy benefits should not be claimed on purely theoretical grounds to justify some loss in efficacy. For instance, recent history has thought us that perceived non-efficacy benefits may actually not be present at all, or perform worse than usual care in studies comparing a bioresorbable vascular scaffold to drug-eluting coronary stents [64]. These scaffolds were designed to require a shorter window of antithrombotic medication after implantation, whilst having fewer rare late thrombotic complications seen with conventional stents. A number of trials demonstrated non-inferiority of scaffolds on early thrombotic complications during the window where less antithrombotic medication had to be used. However, long-term follow-up of these trials revealed that late thrombotic complications actually occurred more frequently with scaffolds compared to stents, which could only be mitigated by prolonged intensified antithrombotic medication use. So the journey of these scaffold started out with the assumption that less antithrombotic medication was needed compared to with stents, justifying non-inferiority studies at the time. In the end, longer antithrombotic therapy than is common with stents was required. Consequently, the manufacturer discontinued sales of these bioresorbable vascular scaffolds. This example serves as a lesson that non-efficacy benefits should not be claimed on theoretical grounds, but must either be obvious (e.g. clear convenience of use or massive cost savings) or be scientifically proven (e.g. fewer adverse events).

From a conceptual standpoint, the usual care arm of a non-inferiority trial should encompass a treatment or diagnostic test with established merits [3]. However, we encountered 6 trials with a placebo arm as the usual care group [18, 29, 30, 34, 38, 55]. These trials were all mandated by regulatory bodies (e.g. FDA) to demonstrate cardiovascular safety of novel non-cardiovascular medication over placebo. This makes for a unique counterintuitive design aiming to study whether non-efficacy outcomes remain below a certain acceptable limits (i.e. the non-inferiority margin), with the previously proven efficacy outcomes acting as non-efficacy benefits. Regulatory safety trials with active treatment in the usual care arm, instead of placebo, are generally easier to interpret [46].

Other than presence of any non-efficacy benefit to justify a non-inferiority study, the non-efficacy benefit should also be proportional to the allowed loss in efficacy (i.e. magnitude of the non-inferiority margin). Although this balancing act is often a matter of clinical judgement, for some tradeoffs empirical data may be available to inform decision making. For instance, when studying de-intensification of antithrombotic therapy, patient-reported quality of life after bleeding or thromboembolic events and associated health care costs are widely available. In our literature review, some of the trials tested expedited discharge algorithms for patients with chest pain in the emergency department. One trial demonstrated that such an algorithm could shorten the average stay in the emergency department by 3.3 h, whilst allowing a relative 71% increase in missed myocardial infarctions (i.e. anticipated relative non-inferiority margin 1.71) [53]. The other trial demonstrated a shortening of stay by 1 h, whilst allowing for a near threefold increase in missed myocardial infarctions (i.e. anticipated relative non-inferiority margin 2.67) [12]. It is highly debatable whether such large non-inferiority margins are clinically acceptable when put into perspective to the limited non-efficacy benefits.

**Composite endpoints including the non-efficacy benefit**

A number of studies in our literature review combined non-efficacy benefits with loss of efficacy outcomes in a composite endpoint tested for non-inferiority, often referred to as *net clinical benefit* endpoints [5, 7, 13, 40, 44]. This is conceptually problematic, since the point of a non-inferiority trial is to balance non-inferiority gains against loss in efficacy. For example, one of these trials aimed to optimize the balance
between thrombotic risk and bleeding one month after coronary stent implantation by halving the dose of an antithrombotic drug, expecting to lower bleeding risk (non-efficacy benefit), whilst accepting a relative 31% increase in clinical events (i.e. anticipated relative non-inferiority margin 1.31) [44]. These clinical events included a range of thrombotic complications and death, but also bleeding complications.

Combining non-efficacy benefits and efficacy outcomes into a composite endpoint dilutes the efficacy comparison, and assuming that non-efficacy benefits are present, can even balance out unacceptable losses in efficacy that cannot be directly unmasked. This will bias the results towards rejecting the null hypothesis of non-inferiority. In the aforementioned trial, the lower dose of antithrombotic drugs was not only found to be non-inferior, but even superior to full dose for the primary endpoint [44]. Thrombotic and bleeding events were also reported separately, revealing that the primary endpoint was completely driven by a halving the number of major bleeding with low dose antithrombotic drugs. Thrombotic events were rare in both treatment groups to an extent that non-inferiority could not have been established if the primary endpoint would have been restricted to thrombotic events only (upper bound of the 95% confidence interval 1.45). This basically reduces the trial results to demonstrating that reduced dose antithrombotics comes with fewer bleeding complications, but it remains uncertain what the effects are on loss of efficacy.

**Incomplete outcome ascertainment**

Incomplete follow-up for outcomes lowers event rates, hence biasing the trial towards claiming non-inferiority when absolute non-inferiority margins are used. An example of a tell-tale sign of incomplete follow-up is the unexpected low ratio of non-fatal myocardial infarctions to cardiac deaths [57].

**The road forward**

The non-inferiority trial is a useful but vulnerable construct and clinicians and researchers should take a few key points in mind when considering non-efficacy benefits and non-inferiority margins in a trial. First, it should only be employed when non-efficacy benefits can be discerned with certainty, and balanced against potential accepted losses in efficacy (i.e. the magnitude of the non-inferiority margin) as described by Dr Acuna and colleagues [9]. Next, if non-efficacy benefits can be measured, non-efficacy benefits should ideally be the primary outcome tested for superiority and losses in efficacy as a co-primary (or hierarchical secondary) outcome tested for non-inferiority. Finally, in order to reduce the inherent vulnerability and hence avoid bias towards or away from non-inferiority due to unanticipated event rates, use of relative risk-based non-inferiority margins and event-driven follow-up rather than a fixed duration of follow-up is preferred from a methodological perspective.

Non-inferiority trials represent an evolving and increasingly frequent employed trial design in clinical cardiology research. Our scoping literature review shows the diversity in reporting and analytical standards with respect to non-efficacy benefits and non-inferiority margins in contemporary high-impact cardiology trials. These findings highlight the importance of awareness and guidance towards appropriate selection and standardized reporting of non-efficacy benefits and non-inferiority margins, in order to ensure that future non-inferiority trials will provide valid new insights and thereby improve care for patients with heart disease.
Declarations

Data transparency Literature search results and subsequently extracted data are available upon reasonable request from the corresponding author.

Role of the funder Not applicable.

Conflicts of interest All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ware JH, Antman EM. Equivalence trials. N Engl J Med. 1997;337(16):1159–61. https://doi.org/10.1056/NEJM199710163716160.

2. Pocock SJ, Clayton TC, Stone GW. Challenging Issues in clinical trial design: part 4 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol. 2015:66(25):2886–98. https://doi.org/10.1016/j.jacc.2015.10.051.

3. Mauri L, D’Agostino RB Sr. Challenges in the design and interpretation of noninferiority trials. N Engl J Med. 2017;377(14):1357–67. https://doi.org/10.1056/NEJMa1510063.

4. Maddahi J, Lazewatsky J, Udelson JE, et al. Phase-III clinical trial of fluorine-18 flurpiridaz positron emission tomography for evaluation of coronary artery disease. J Am Coll Cardiol. 2020;76(4):391–401. https://doi.org/10.1016/j.jacc.2020.05.063.

5. Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;383(15):1447–57. https://doi.org/10.1056/NEJMoa2017815.

6. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032–42. https://doi.org/10.1056/NEJMoa1908419.

7. Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;382(18):1696–707. https://doi.org/10.1056/NEJMoa1915152.

8. Valgimigl M, Gragnano F, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021;373: n1332. https://doi.org/10.1136/bmj.n1332.

9. Acuna SA, Dossa F, Chesney TR. Improving the reporting of non-inferiority trials by incorporating non-efficacy benefits: not all on-inferiority trials are created equal. Eur J Epidemiol. 2021. https://doi.org/10.1007/s10654-021-00791-z.

10. Byrne RA, Alfonso F, Schneider S, et al. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracorony Scaffold Assessment A Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. Eur Heart J. 2019;40(2):167–76. https://doi.org/10.1093/eurheartj/ehy710.

11. Callum J, Farkouh ME, Scales DC, et al. Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: the fibres randomized clinical trial. JAMA. 2019;322(20):1966–76. https://doi.org/10.1001/jama.2019.17312.

12. Chew DP, Lambrakis K, Blyth A, et al. A randomized trial of a 1-hour troponin t protocol in suspected acute coronary syndromes: the rapid assessment of possible acute coronary syndrome in the emergency department with high-sensitivity troponin t study (RAPID-TsT). Circulation. 2019;140(19):1543–56. https://doi.org/10.1161/CIRCULATIONAHA.119.042891.

13. Claessens DMF, Vos GJA, Bergmeijer TO, et al. A Genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–31. https://doi.org/10.1056/NEJMoa1907096.

14. Franzzone A, McFadden E, Leonardi S, et al. Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting. J Am Coll Cardiol. 2019;74(18):2223–34. https://doi.org/10.1016/j.jacc.2019.08.1038.

15. Garcia-Fernandez FJ, Osca Asensi J, Romero R, et al. Safety and efficiency of a common and simplified protocol for pacemaker and defibrillator surveillance based on remote monitoring only: a long-term randomized trial (RM-ALONE). Eur Heart J. 2019;40(23):1837–46. https://doi.org/10.1093/eurheartj/ehz067.

16. Guihard B, Chollet-Xemard C, Lakhnati P, et al. Effect of rocuronium vs. succinylcholine on endotracheal intubation success rate among patients undergoing out-of-hospital rapid sequence intubation: a randomized clinical trial. JAMA. 2019;322(23):2303–12. https://doi.org/10.1001/jama.2019.18254.

17. Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321(24):2428–37. https://doi.org/10.1001/jama.2019.8146.

18. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51. https://doi.org/10.1056/NEJMoa1901118.

19. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380(5):415–24. https://doi.org/10.1056/NEJMoa1808312.

20. Lanz J, Kim WK, Walther T, et al. Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. Lancet. 2019;394(10209):1619–28. https://doi.org/10.1016/S0140-6736(19)32220-2.

21. Lee SW, Lee PH, Ahn JM, et al. Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion. Circulation. 2019;139(14):1674–83. https://doi.org/10.1161/CIRCULATIONAHA.118.031313.

22. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–24. https://doi.org/10.1056/NEJMoa1817083.

23. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–705. https://doi.org/10.1056/NEJMoa1814052.
24. Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation. 2019;139(5):604–16. https://doi.org/10.1161/CIRCULATIONAHA.118.036768.

25. Nagel E, Greenwood JP, McCann GP, et al. Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl J Med. 2019;380(25):2418–28. https://doi.org/10.1056/NEJMoai1716734.

26. Pluymaekers N, Dudink E, Luermans J, et al. Early or delayed cardioversion in recent-onset atrial fibrillation. N Engl J Med. 2019;380(16):1499–508. https://doi.org/10.1056/NEJMoai1900353.

27. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706–15. https://doi.org/10.1056/NEJMa1816885.

28. Rissanen TT, Uskela S, Eranen J, et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet. 2019;394(10194):230–9. https://doi.org/10.1016/S0140-6736(19)31126-2.

29. Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in patients with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;322(12):1155–66. https://doi.org/10.1001/jama.2019.137722.

30. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of liotiglizin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79. https://doi.org/10.1001/jama.2018.18269.

31. Rozemeijer R, Stein M, Voskuil M, et al. Randomized all-comers evaluation of a permanent polymer zotarolimus-eluting stent versus a polymer-free amphilimus-eluting stent. Circulation. 2019;139(1):67–77. https://doi.org/10.1161/CIRCULATIONAHA.118.037707.

32. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335–45. https://doi.org/10.1016/S0140-6736(19)31872-0.

33. Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321(24):2414–27. https://doi.org/10.1001/jama.2019.8145.

34. Wise RA, Chapman KR, Scirica BM, et al. Effect of alclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: the ASCENT-COPD randomized clinical trial. JAMA. 2019;321(17):1693–701. https://doi.org/10.1001/jama.2019.4973.

35. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoai1812309.

36. Yasuda S, Kikita K, Aka M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103–13. https://doi.org/10.1056/NEJMoai1904143.

37. Zaman A, de Winter RJ, Kogame N, et al. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet. 2019;393(10175):987–97. https://doi.org/10.1016/S0140-6736(18)32467-X.

38. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–35. https://doi.org/10.1056/NEJMoa2004967.

39. Gargiulo G, Esposito G, Avvedimento M, et al. Cangrelor, tiopronin, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABoLUS-FASTER trial. Circulation. 2020;142(5):441–54. https://doi.org/10.1161/CIRCULATIONAHA.120.046928.

40. Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020;395(10233):1374–81. https://doi.org/10.1016/S0140-6736(20)30325-1.

41. Guimaraes HP, Lopes RD, deBarros ESPGM, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383(22):2117–26. https://doi.org/10.1056/NEJMoa2092603.

42. Holm NR, Makikallio T, Lindsay MM, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet. 2020;395(10219):191–9. https://doi.org/10.1016/S0140-6736(19)32972-1.

43. Jensen LO, Maeng M, Raungaard B, et al. Randomized comparison of the polymer-free Biolimus-coated biofreedom stent with the ultrathin strut biodegradable polymer Sirolimus-eluting Orsio stent in an all-comers population treated with percutaneous coronary intervention: the SORT OUT IX trial. Circulation. 2020;141(25):2052–63. https://doi.org/10.1161/CIRCULATIONAHA.119.040241.

44. Kim HS, Kang J, Hwang D, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020;396(10257):1079–89. https://doi.org/10.1016/S0140-6736(20)31791-8.

45. Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med. 2020;383(6):526–36. https://doi.org/10.1056/NEJMoai1915932.

46. Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745–57. https://doi.org/10.1016/S0140-6736(20)32234-0.

47. Makkar RR, Cheng W, Wakmsman R, et al. Self-expanding intranunnular versus commercially available transcatheter hearth valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial. Lancet. 2020;396(10252):669–83. https://doi.org/10.1016/S0140-6736(20)31358-1.

48. Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2020;75(25):3122–35. https://doi.org/10.1016/j.jacc.2020.04.067.

49. Sheppard JP, Burt J, Lown M, et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the OPTIMISE randomized clinical trial. JAMA. 2020;323(20):2093–91. https://doi.org/10.1001/jama.2020.4871.

50. Tamburino C, Bleiziffer S, Thiele H, et al. Comparison of self-expanding bioprostheses for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: SCOPE 2 randomized clinical trial. Circulation. 2020;142(25):2431–42. https://doi.org/10.1161/CIRCULATIONAHA.120.051547.
51. van den Dries CJ, van Doorn S, Rutten FH, et al. Integrated management of atrial fibrillation in primary care: results of the ALL-IN cluster randomized trial. Eur Heart J. 2020;41(30):2836–44. https://doi.org/10.1093/eurheartj/ehaa055.
52. Windecker S, Latib A, Kedhi E, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med. 2020;382(13):1208–18. https://doi.org/10.1056/NEJMoa1910021.
53. Anand A, Lee KK, Chapman AR, et al. High-sensitivity cardiac troponin on presentation to rule out myocardial infarction: a stepped-wedge cluster randomized controlled trial. Circulation. 2021;143(23):2214–24. https://doi.org/10.1161/CIRCULATIONNAHA.120.052380.
54. Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, et al. Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: The REALITY randomized clinical trial. JAMA. 2021;325(6):552–60. https://doi.org/10.1001/jama.2021.0135.
55. Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2108269.
56. Jakobsen L, Christiansen EH, Freeman P, et al. Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting combo stent with the sirolimus-eluting orsiro stent in patients treated with percutaneous coronary intervention: the SORT OUT X Trial. Circulation. 2021;143(22):2155–65. https://doi.org/10.1161/CIRCULATIONNAHA.120.052766.
57. Kim HS, Kang J, Hwang D, et al. Durable polymer versus biodegradable polymer drug-eluting stents after percutaneous coronary intervention in patients with acute coronary syndrome: the HOST-REDUCE-POLYTECH-ACS trial. Circulation. 2021;143(11):1081–91. https://doi.org/10.1161/CIRCULATIONNAHA.120.051700.
58. Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (Amulet IDE): a randomized controlled trial. Circulation. 2021. https://doi.org/10.1161/CIRCULATIONNAHA.121.057063.
59. Lansky AJ, Kereiakes DJ, Baumbach A, et al. Novel supreme drug-eluting stents with early synchronized antiproliferative drug delivery to inhibit smooth muscle cell proliferation after drug-eluting stents implantation in coronary artery disease: results of the PIONEER III randomized clinical trial. Circulation. 2021;143(22):2143–54. https://doi.org/10.1161/CIRCULATIONNAHA.120.052482.
60. Nakashima CAK, Dallan LAO, Lisboa LAF, et al. Platelet reactivity in patients with acute coronary syndromes awaiting surgical revascularization. J Am Coll Cardiol. 2021;77(10):1277–86. https://doi.org/10.1016/j.jacc.2021.01.015.
61. Peyster EG, Arabayarmohammadi S, Janowczyk A, et al. An automated computational image analysis pipeline for histological grading of cardiac allograft rejection. Eur Heart J. 2021;42(24):2356–69. https://doi.org/10.1093/eurheartj/ehab241.
62. Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2108749.
63. Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2111016.
64. Ali ZA, Serruys PW, Kimura T, et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet. 2017;390(10096):760–72. https://doi.org/10.1016/S0140-6736(17)31470-8.
65. Mo Y, Lim C, Watson IA, White NJ, Cooper BS. Non-adherence in non-inferiority trials: pitfalls and recommendations. BMJ. 2020;370: m2215. https://doi.org/10.1136/bmj.m2215.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.